Search academic texts

Information × Registration Number 0220U100519, 0118U100240 , R & D reports Title Enhancement of anticancer activity of landomycin A by its immobilization on the poly-2-oxazoline nanocarrier: effects in vitro and in vivo popup.stage_title Head Panchuk Rostyslav Ruslanovych, Доктор біологічних наук Registration Date 21-01-2020 Organization Institute of Cell Biology popup.description2 During phase I of the project in 2018, potential molecular targets of landomycin A in malignant cells were investigated in silico and tested in vitro by flow cytometry. During implementation of Phase II of the grant in 2019 the unique ability of landomycin A to form adducts with thiol-containing compounds was revealed. Key role of this phenomenon in circumvention of acquired tumor drug resistance in malignant cells by LA was demonstrated. Another unique feature of landomycins that distinguishes them from other antitumor antibiotics is early activation of caspase-7 and the cleavage of the PARP-1 protein, which precedes depolarization of mitochondria. Such specific feature of landomycins’ remain unchanged both in chemotherapy-sensitive cells and in their drug-resistant sublines. At the final stage of the work, preclinical studies of the therapeutic effect of novel pharmaceutical form of landomycin A towards murine B16 melanoma were performed. LA was found to exhibit significantly less side effects than well-known anticancer drug doxorubicin, with comparable therapeutic activity. At the same time, immobilization of LA on a poly-2-oxazoline carrier exhibited a powerful synergistic effect, leading to complete remission of B16 melanoma in animals. The obtained results were published in the peer-reviewed magazine Cellular and Molecular Bioengineering, and are of high value for clinical oncology.  Product Description popup.authors Kozak Yuliya S. Skorokhyd Nadiya R. popup.nrat_date 2020-04-02 Close